

August 1, 2023

Notice Regarding Recalculated 340B Ceiling Prices for 3Q2020

Johnson & Johnson Health Care Systems Inc., (“JJHCS”) on behalf of Johnson & Johnson companies participating in the 340B program (Janssen Biotech, Inc.) (“Janssen”) has asked the Office of Pharmacy Affairs (OPA) to post this notice on OPA’s public website to ensure transparency.

Janssen has revised 3Q2020 340B pricing on covered outpatient drugs. The revisions were due to standard restatements of Medicaid pricing data made to CMS. As a result of the recalculated 340B Ceiling Prices, Janssen has determined that, a refund is or may be owed to 340B Covered Entities that purchased any of the below NDCs during the period of July 1, 2020 through September 30, 2020.

Janssen will be communicating with and issuing refund adjustments through the wholesalers that submitted the original sale on behalf of the 340B covered entities. If you feel you have not received an appropriate adjustment, please contact Janssen via email at: ra-hcsus-govcontract@its.jnj.com with a subject line of “340B Standard Refile” and your entities 340B ID. In addition, please include in the body of your email: NDC Number, Quantity, Original Purchase Invoice Number, Invoice Date, and the Wholesaler the product was purchased through for all affected products so that we can research your inquiry further.

NDC 11	NDC Description	Quarter/Year
57894-0640-01	TREMFYA 1X100MG USAFEPL USA	3Q20
57894-0640-11	TREMFYA 1X100MG ONE PR. USA	3Q20
59676-0312-04	PROCRIT 10000 U/ML MD VIAL 4S	3Q20